Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data

Journal of Cutaneous Medicine and Surgery

Volumn 10, Issue 6, 2006, Pages 277-280

  Rennie, Robert P ^a,b  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FUSIDIC ACID; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATION; BACTERIUM CULTURE; DISK DIFFUSION; EPIDEMIC; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY DISK DIFFUSION TEST; CANADA; CLASSIFICATION; CROSS INFECTION; DRUG EFFECT; GENETICS; HEALTH SURVEY; HUMAN; MICROBIOLOGICAL EXAMINATION; PENICILLIN RESISTANCE; STAPHYLOCOCCUS INFECTION; TEACHING HOSPITAL;

ANTI-BACTERIAL AGENTS; CANADA; CROSS INFECTION; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, BACTERIAL; FUSIDIC ACID; HOSPITALS, TEACHING; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33947535065     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2006.00064     Document Type: Article

References (10)

1. Ferraro MJ. Should we reevaluate antibiotic breakpoints? Clin Infect Dis 2001;33 Suppl 3:S227-9.
2. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003;7 Suppl 1:S13-20.
3. Winkelman W, Gratton D. Topical antibacterials. Clin Dermatol 1989;7:156-62.
4. Stüttgen G, Bauer E. Penetration and permeation into human skin of fusidic acid in different galenical formulations. Arzneimittelforschung 1988;38:730-5.
5. LEO Pharma Inc. Fucidin Leo [product monograph]. 1993.
6. Laverdière M, Weiss K, Rivest R, Delorme J. Trends in antibiotic resistance of staphylococci over an eight-year period: differences in the emergence of resistance between coagulase positive and coagulase-negative staphylococci. Microbial Drug Resist 1998;4:119-22.
7. Toma E, Barriault D. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci. J Clin Microbiol 1995;33:1712-5.
8. ONeill C, Vanzuilen L, Dunnett S, et al. Mupirocin resistance in methicillin resistance Staphylococcus aureus (MRSA) in the Niagara Region, Ontario [abstract]. Presented at the 2002 Conference of the Canadian Association for Clinical Microbiology and Infectious Diseases. Available at: http://www.cacmid.ca/abstracts_02/d2.htm (accessed 2002).
9. Weiss K, Restieri C, Guay H, et al. Methicillin resistant Staphylococcus aureus (MRSA) prevalence in Québec, Canada, and in vitro activity of fusidic acid, linezolid, quinupristin-dalfopristin and rifampin against MRSA strains [abstract]. In: 42nd ICAAC Abstracts, American Society of Microbiology, September 27-30, 2002, San Diego, CA. American Society for Microbiology; 88.
10. IMS Canada. Compuscript for the MAT ending July 2005. Available at: www.imshealthcanada.com.